Japan Pharmas Clear Fiscal Year With Mixed Bag Of Results
This article was originally published in PharmAsia News
Executive Summary
Japan's major drug makers finished the fiscal year's first quarter with mixed results for investors, spanning a height of Takeda Pharmaceutical's 18% growth to Daiichi Sankyo's 24% profit decline